This is spring loaded waiting to go off. $40-50m mc is nothing if any one of there immunotherapies are shown to either work as a standalone product or help other pharma companies drugs work much more effectively. IMU got to a $3b mc on zero revenue. All the small biotech have pulled back, but the tide may turn just as we show positive results. I'm staying in.
Ann: CBCF funding to support deoxymab brain cancer development, page-6
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
-0.001(14.3%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.6¢ | $4.61K | 768.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 728075 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 3743101 | 5 |
View Market Depth
| Last trade - 15.05pm 12/08/2024 (20 minute delay) ? |
| PAB (ASX) Chart |